Financial Performance - Research and development expenses decreased by 9% to $5.8 million for the year ended December 31, 2025, down from $6.3 million in 2024, primarily due to reduced clinical trial costs and personnel expenses [430]. - General and administrative expenses increased by 56% to $6.7 million for the year ended December 31, 2025, compared to $4.3 million in 2024, mainly due to higher professional fees and share-based compensation [431]. - The company reported an accumulated deficit of $156.7 million as of December 31, 2025, reflecting ongoing operating losses since inception [437]. - Other expenses increased to approximately $32,400 in 2025, compared to income of approximately $331,000 in 2024, primarily due to foreign currency exchange losses [433]. - Net cash used in operating activities for the years ended December 31, 2025 and 2024 was $5.9 million and $9.6 million, respectively, indicating a decrease in cash burn [442]. - The company acknowledges substantial doubt about its ability to continue as a going concern for a period of one year after the filing date of the Annual Report [440]. Product Development - The most advanced product candidate, agenT-797, has treated nearly 100 patients, demonstrating significant clinical insights in oncology and critical pulmonary immune failure [422]. - In a Phase 1 clinical trial, agenT-797 showed a median overall survival of approximately 23 months in combination with anti-PD-1 therapies for heavily pretreated patients [426]. - A Phase 2 trial for agenT-797 in combination with botensilimab and balstilimab is ongoing, with early data indicating robust immune activation in patients with gastroesophageal cancers [427]. - The company has initiated IND-enabling studies for next-generation engineered iNKT programs, including MiNK-413 and MiNK-215, targeting BCMA and FAP, respectively [428]. Funding and Liquidity - The company entered into a Sales Agreement to sell shares of common stock with a maximum aggregate offering price of $50 million, raising $17.5 million in net proceeds by March 27, 2026 [438]. - As of December 31, 2025, the company had a cash and cash equivalents balance of $13.4 million, which is expected to meet liquidity requirements for more than one year [440]. - The company repaid a Note in full in January 2026, which had an outstanding principal of $5.0 million plus accrued interest of approximately $179,000 [439]. - In May 2024, the company issued and sold 464,000 shares of common stock at a price of $12.50 per share, raising approximately $5.8 million [439]. - Future cash generation will depend on achieving regulatory approval and market acceptance of product candidates, as well as entering into collaborations [442]. - The company is exploring additional funding sources, including strategic partnerships, non-dilutive financing, and potential equity or debt financing options [441]. Regulatory and Compliance - The company qualifies as an "emerging growth company" under the JOBS Act, allowing it to take advantage of reduced disclosure requirements [447]. - The company has not opted out of the extended transition period for complying with new accounting standards, which may affect comparability with other public companies [450]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures [452].

Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of $13.4 million, an increase from $4.6 million in 2024, while operating costs decreased nearly 40% over the year [14][19] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to $2.5 million or $0.62 per share for Q4 2024. For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024 [19] Business Line Data and Key Metrics Changes - MiNK cells are in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions, demonstrating durable survival beyond 23 months and complete remission extending beyond two years in heavily pretreated refractory cancers [3][6] - The company is advancing trials in graft versus host disease (GVHD) and severe hypoxemic pneumonia, with significant external funding secured for these initiatives [4][11] Market Data and Key Metrics Changes - The hypoxemic pneumonia market affects approximately 200-300,000 patients annually, with a mortality rate of 30%-40% and no approved disease-modifying therapies [8][10] - The company is targeting a specific patient population for its ARDS trial, utilizing a global ARDS definition to ensure precise selection based on oxygenation and organ function [35] Company Strategy and Development Direction - The company is focused on capital efficiency, combining disciplined internal execution with non-dilutive funding through government and institutional partnerships [5][12] - The strategic approach includes advancing a PRAME-targeted TCR-engineered iNKT program, leveraging collaborations to enhance platform capabilities without significant capital burden [13][14] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of demonstrating durability and mechanistic validation of their technology in 2025, setting the stage for future clinical advancements [21] - The company expects to initiate a randomized phase II/III ARDS study and dosing in the GVHD trial in the first half of 2026, with initial clinical data anticipated in the second half of the year [17][21] Other Important Information - The company has appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has secured multiple sources of non-dilutive capital funding, including NIH funding and philanthropic support, to advance clinical programs and expand the pipeline [12][14] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study, including patient numbers and control arm? - Management indicated that the trial will involve patients treated with standard care, with the MiNK cells added on top, emphasizing the unique ability of the cells to modulate immune function even in the presence of steroids [25][26] Question: What is the status of the second-line gastric cancer trial and when will efficacy data be available? - Efficacy data from the gastric cancer trial is expected to be presented at a major conference in the first half of the year [29] Question: What differentiating aspects does the company consider for IPF and GVHD patient populations? - Management highlighted the immune-related nature of IPF and the potential for MiNK cells to provide benefits, with plans for a responsible funding approach for the trial [30][33] Question: Can you clarify the combination approach with the IL-15 iNKT cell trial? - Management clarified that no formal announcement has been made regarding collaborations with IL-15 superagonists, and any strategic collaborations will be publicly disclosed at the appropriate time [44][45]

Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of $13.4 million, an increase from $4.6 million in the previous year, while operating costs decreased nearly 40% [14][20] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to $2.5 million or $0.62 per share for Q4 2024. For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024 [20] Business Line Data and Key Metrics Changes - MiNK cells are currently in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions, demonstrating durable survival beyond 23 months in heavily pretreated refractory cancers [3][6] - The company is advancing a trial in graft versus host disease (GVHD) and a phase II trial in gastric cancer, with results expected to be presented at a major conference in the first half of 2026 [4][11] Market Data and Key Metrics Changes - The company is targeting a significant patient population for hypoxemic pneumonia or ARDS, affecting approximately 200,000-300,000 patients annually, with a mortality rate of 30%-40% [8][10] - The company has observed substantial clinical activity in patients with severe acute respiratory distress, showing prolonged survival rates compared to hospital controls [9] Company Strategy and Development Direction - The company is focused on capital efficiency, combining disciplined internal execution with non-dilutive funding through government and institutional partnerships [5][12] - The strategic collaboration with the C-Further Consortium aims to advance the PRAME-targeted TCR-engineered iNKT program, reflecting external validation of the platform's maturity [13][14] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of generating clear, interpretable data to inform future development and regulatory pathways, with multiple readouts planned for the first half of 2026 [17][22] - The company is excited about the upcoming randomized controlled clinical trials and anticipates initial clinical data in the second half of 2026 [22] Other Important Information - The company has appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has secured multiple sources of non-dilutive capital funding, including NIH funding and philanthropic support, to advance clinical programs without diluting shareholder equity [12][14] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study and the control arm? - Management indicated that the trial will involve patients treated with standard of care, primarily steroid therapy, and that the cells will be added on top of this standard [25][26] Question: What is the status of the second-line gastric cancer trial? - Efficacy data from the gastric cancer trial is expected to be presented in the first half of 2026 at a major conference [31] Question: What differentiating aspects does the company consider for IPF and GVHD? - Management noted that the patient populations for ARDS will be specifically identified based on oxygenation and organ function, with no approved therapies currently available [35][38] Question: Can you clarify the combination approach with the IL-15 iNKT cell trial? - Management clarified that the company has not formally announced any collaboration regarding the IL-15 superagonist and will be public about any strategic collaborations in the future [46][48]

Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of approximately $13.4 million, an increase from $4.6 million in the previous year [14] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to a net loss of $2.5 million or $0.62 per share in Q4 2024 [19] - For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024, reflecting continued investment in clinical programs while controlling operational spending [19] Business Line Data and Key Metrics Changes - The company is advancing its MiNK iNKT cell platform, which is currently in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions [3][4] - Clinical activity has been observed in patients with hypoxemic pneumonia, with a planned randomized phase II trial to begin soon [4][10] - The company has secured external funding for trials in graft versus host disease (GVHD) and gastric cancer, with results expected to be presented at major conferences [4][11] Market Data and Key Metrics Changes - The company is targeting a significant patient population for its hypoxemic pneumonia treatment, which affects approximately 200,000 to 300,000 patients annually with a mortality rate of 30%-40% [8][10] - The company is also focusing on the pediatric oncology market through its collaboration with the C-Further Consortium, which reflects external validation of its platform [13] Company Strategy and Development Direction - The company aims to restore immune function in various diseases, leveraging a capital-efficient model that combines internal execution with non-dilutive funding [5][12] - The strategy includes advancing clinical programs in immune-mediated diseases without incremental capital burden, supported by non-dilutive funding sources [12][14] - The company plans to initiate a randomized phase II/III study for ARDS and activate its GVHD trial in 2026, with initial clinical data expected in the second half of the year [17] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of demonstrating durability and mechanistic validation of their technology in 2025, setting the stage for future clinical advancements [21] - The company is focused on generating clear, interpretable data to inform development and regulatory pathways, with multiple readouts planned for 2026 [17] Other Important Information - The company appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has seen increased external interest in its iNKT biology and is exploring strategic partnerships, although no formal collaborations have been announced yet [16][45] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study, including patient numbers and control arms? - The company has not publicly posted the program details but will use physician's choice as the control arm, with the cells added on top of standard care [25][26] Question: What is the status of the second-line gastric cancer trial and when will efficacy data be available? - Efficacy data from the gastric cancer trial will be presented in the first half of the year at a major conference [30] Question: What differentiating aspects does the company consider for IPF and GVHD patient populations? - The company is focusing on immune-related conditions and has preclinical observations supporting the development of cells in IPF [34][36] Question: Can you clarify the IL-15 iNKT cell combination trial and its relation to the randomized controlled trial in ARDS? - The company has not formally announced any collaboration regarding the IL-15 superagonist and will provide updates when appropriate [44][45]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 MiNK Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 149 Fifth Avenue Suite 500 New York, New York 10010 (Address of Principal Executive Offices) (Zip Code) Delaware 001-40908 82-2142067 (Commission File Num ...

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing non-dilutive funding for PRAME-TCR iNKT in pediatric oncologyNIH STTR grant and Mary Gooze philanthropic award fully fund graft-versus-host disease (GVHD) preclinical data with clinical trial launch in 1H 2026Keystone Symposia data report iNKT depletion in end-stage Pulmonary Fibrosis (IPF); underscores pipeli ...

Core Viewpoint - MiNK Therapeutics, Inc. is set to report its financial results for Q4 and the full year of 2025 on March 31, 2026, and will provide updates on its clinical progress and strategic initiatives in iNKT cell therapies [1][2]. Financial Results Announcement - The financial results will be disclosed before the market opens on March 31, 2026 [1]. - A conference call and webcast will be held at 8:30 a.m. ET on the same day to discuss the results and corporate updates [2]. Recent Developments - MiNK has announced a collaboration with C-Further and the University of Southampton to develop a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers [3]. - This collaboration is expected to provide non-dilutive funding and significant commercial revenue potential, validating MiNK's iNKT platform in engineered cell therapy [3][4]. Strategic Expansion - The collaboration aligns with MiNK's strategy to expand its iNKT platform through clinical-stage programs and engineered cell therapies targeting validated tumor antigens [4]. - The company aims to leverage external partnerships to advance its programs in a capital-efficient manner [4]. Company Overview - MiNK Therapeutics is focused on developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators to restore immune balance and enhance cytotoxic responses [6]. - The lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for various conditions, including solid tumors and graft-versus-host disease [7]. - MiNK's pipeline includes TCR-based and neoantigen-targeted iNKT programs, with a scalable manufacturing process aimed at delivering durable and accessible treatments [7].

MiNK Therapeutics Inc. (NASDAQ:INKT) shares are down during Wednesday’s premarket session, possibly on profit-taking after the stock rallied roughly 30% on Tuesday.On Tuesday, the company announced a strategic collaboration aimed at developing a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.$1.1 Million Funding for MiNK Therapeutics PRAME-TCR-iNKT AssetUnder the collaboration, MiNK Therapeutics will receive approximately $1.1 million in non-dilutive funding to support the development ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Group 1: Premarket Gainers - Domo, Inc. (DOMO) is up 39% at $6.13 [3] - Auna SA (AUNA) is up 17% at $5.67 [3] - TMD Energy Limited (TMDE) is up 16% at $2.39 [3] - Acurx Pharmaceuticals, Inc. (ACXP) is up 14% at $3.31 [3] - Atomera Incorporated (ATOM) is up 11% at $5.58 [3] - Oracle Corporation (ORCL) is up 9% at $163.42 [3] - UniFirst Corporation (UNF) is up 8% at $280.84 [3] - Adial Pharmaceuticals, Inc. (ADIL) is up 8% at $1.99 [3] - VCI Global Limited (VCIG) is up 7% at $3.22 [3] - XTI Aerospace, Inc. (XTIA) is up 5% at $3.19 [3] Group 2: Premarket Losers - Raytech Holding Limited (RAY) is down 22% at $3.40 [4] - MiNK Therapeutics, Inc. (INKT) is down 15% at $11.39 [4] - ESGL Holdings Limited (OIO) is down 15% at $3.26 [4] - Trailblazer Holdings, Inc. (TBMC) is down 14% at $10.13 [4] - Groupon, Inc. (GRPN) is down 12% at $10.16 [4] - AeroVironment, Inc. (AVAV) is down 10% at $198.24 [4] - Brand Engagement Network, Inc. (BNAI) is down 10% at $32.83 [4] - Polaryx Therapeutics, Inc. (PLYX) is down 7% at $5.50 [4] - TIC Solutions, Inc. (TIC) is down 6% at $8.00 [4] - ENDRA Life Sciences Inc. (NDRA) is down 5% at $3.32 [4]

Collaboration Overview - MiNK Therapeutics has entered a collaboration that provides approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset, along with a double-digit share of downstream commercial revenues [1][2] Strategic Focus - The partnership aligns with MiNK's broader strategy to utilize its iNKT platform across validated tumor antigens, emphasizing safety and long-term survivorship while allowing for independent pursuit of other tumor antigen targets [2] iNKT Cell Therapy Advantages - iNKT cells are an allogeneic, off-the-shelf therapy derived from healthy donors, which can be manufactured in advance, cryopreserved, and delivered without the need for HLA matching or toxic lymphodepleting chemotherapy [3] Clinical Data Highlights - MiNK Therapeutics reported a landmark case published in Nature's Oncogene, showcasing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer after treatment with agenT-797, MiNK's allogeneic iNKT cell therapy [4] Treatment Tolerability - Donor iNKT cells were detectable up to six months post-infusion, and the treatment was well-tolerated, showing no signs of cytokine release syndrome or graft-versus-host disease [5] Market Reaction - Following the news, MiNK Therapeutics shares increased by 48.33%, reaching $15.50 [5]